| Company Name: | Generex Biotechnology Corporation | | Ticker Symbol: | GNBT | | | WWW Address: | www.generex.com | | CEO: | Anna E. Gluskin | | No. of Employees: | 43 | | Common Issue Type: | CS | | Business Description: | A development stage Company, engaged in the research, development, and commercialization of drug delivery systems and technologies for metabolic and immunological diseases.
|
| | | Industry Information: | DRUGS - Drug Delivery [more like this] |
| | Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 0.495 |  -0.005 | 0.4751 | 0.5 | 0.5 | 0.51 | 0.46 | 1541670 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 123.5 | 246.9 | 1.73 | -0.32 | 0.00 | 0.0 | 0.0 | 1.14 - 0.08 |
| | KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 0.50 | $ | | PE Ratio - LTM | 0.0 | |
| Market Capitalisation | 123.5 | mil |
| Latest Shares Outstanding | 246.9 | mil |
| Earnings pS (EPS) | -0.32 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | 0 | % |
| Revenue per Employee | 26,023 | $ |
| Effective Tax Rate | 0.0 | % |
| Float | 245.2 | mil |
| Float as % of Shares Outstanding | 99.3 | % |
| Foreign Sales | 0 | mil |
| Domestic Sales | 0 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 1,187.20 | % |
| Research & Devlopment (R&D) as % of Revenue | 1,212.00 | % |
| Gross Profit Margin | 0.0 | % |
| EBITDA Margin | 0.0 | % |
| Pre-Tax Profit Margin | 0.0 | % |
| Assets Turnover | 0.0 | % |
| Return on Assets (ROA) | -184.6 | % |
| Return on Equity (ROE) | 0.0 | % |
| Return on Capital Invested (ROCI) | -284.9 | % |
| Current Ratio | 1.9 | |
| Leverage Ratio (Assets/Equity) | 1.7 | |
| Interest Cover | 0.0 | |
| Total Debt/Equity (Gearing Ratio) | 0.21 | |
| LT Debt/Total Capital | 12.0 | % |
| Working Capital pS | 0.03 | $ |
| Cash pS | 0.06 | $ |
| Book-Value pS | 0.06 | $ |
| Tangible Book-Value pS | 0.04 | $ |
| Cash Flow pS | -0.12 | $ |
| Free Cash Flow pS | -0.09 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 8.68 | |
| Price/Tangible Book Ratio | 11.73 | |
| Price/Cash Flow | -4.2 | |
| Price/Free Cash Flow | -5.4 | |
| P/E as % of Industry Group | 0.0 | % |
| P/E as % of Sector Segment | 0.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | | | | | PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | -3.8 | 96 | 13,033 | 62,388 |
| 4 Weeks | 0.64 | 0.45 | 0.62 | -18.7 | 80 | 21,824 | 436,486 |
| 13 Weeks | 1.01 | 0.45 | 0.61 | -18.0 | 77 | 54,913 | 3,514,460 |
| 26 Weeks | 1.14 | 0.35 | 0.37 | 36.6 | 111 | 71,437 | 9,072,539 |
| 52 Weeks | 1.14 | 0.08 | 0.34 | 49.3 | 109 | 50,664 | 12,716,695 |
| YTD | 1.14 | 0.08 | - | 61.3 | 133 | 55,553 | 12,499,473 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 0.51 | 0.52 | 0.63 | 0.59 | 0.51 | 1.73 | 1.93 |
| | | | GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | -1.44 | 0.1 | 68.20 |
| Income | 0.00 | 0.0 | 0.00 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | -6.87 | NA | -15.29 |
| R&D | 16.10 | NA | 30.52 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | 796.0 | 68.3 | 796.0 |
| Earnings % | 0.0 | 0.0 | 0.0 |
| EPS % | 0.0 | 0.0 | 0.0 |
| EPS $ | 0.01 | 0.06 | 0.01 |
| | | | SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 30.47 |
| Current Ratio | 1.9 |
| Quick Ratio (Acid Test) | 1.6 |
| Liquidity Ratio (Cash) | 1.63 |
| Receivables Turnover | 16.0 |
| Average Collection Period | 23 |
| Working Capital/Equity | 53.2 |
| Working Capital pS | 0.03 |
| Cash-Flow pS | -0.12 |
| Free Cash-Flow pS | -0.09 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 1.36 |
| Financial Leverage Ratio (Assets/Equity) | 1.7 |
| Debt Ratio | 42.7 |
| Total Debt/Equity (Gearing Ratio) | 0.21 |
| LT Debt/Equity | 0.13 |
| LT Debt/Capital Invested | 11.6 |
| LT Debt/Total Liabilities | 17.5 |
| Interest Cover | 0.0 |
| Interest/Capital Invested | 125.08 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 6.45 |
| Tobin's Q Ratio | 4.98 |
| Current P/E Ratio - LTM | 0.00 |
| Enterprise Value (EV)/EBITDA | -12.61 |
| Enterprise Value (EV)/Free Cash Flow | -4.84 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | 11.73 |
| Price/Book Ratio - LTM | 8.68 |
| Price/Cash Flow Ratio | -4.2 |
| Price/Free Cash Flow Ratio - LTM | -5.4 |
| Price/Sales Ratio | 110.34 |
| P/E Ratio (1 month ago) - LTM | 0.0 |
| P/E Ratio (26 weeks ago) - LTM | 0.0 |
| P/E Ratio (52 weeks ago) - LTM | 0.0 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | 0 |
| P/E as % of Industry Group | 0.0 |
| P/E as % of Sector Segment | 0.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 0.0 |
| PER SHARE FIGURES |
| LT Debt pS | 0.01 |
| Current Liabilities pS | 0.04 |
| Tangible Book Value pS - LTM | 0.04 |
| Book Value pS - LTM | 0.06 |
| Capital Invested pS | 0.07 |
| Cash pS - LTM | 0.06 |
| Cash Flow pS - LTM | -0.12 |
| Free Cash Flow pS - LTM | -0.09 |
| Earnings pS (EPS) | -0.32 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | -2,037.71 |
| Free Cash Flow Margin 5YEAR AVG | -8,756.73 |
| Net Profit Margin | 0.0 |
| Net Profit Margin - 5YEAR AVRG. | 0.0 |
| Equity Productivity | 0.08 |
| Return on Equity (ROE) | 0.0 |
| Return on Equity (ROE) - 5YEAR AVRG. | 0.0 |
| Capital Invested Productivity | 0.07 |
| Return on Capital Invested (ROCI) | -284.9 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | -137.0 |
| Assets Productivity | 0.00 |
| Return on Assets (ROA) | -184.6 |
| Return on Assets (ROA) - 5YEAR AVRG. | -105.7 |
| Gross Profit Margin | 0.0 |
| Gross Profit Margin - 5YEAR AVRG. | 0.0 |
| EBITDA Margin - LTM | 0.0 |
| EBIT Margin - LTM | 0.0 |
| Pre-Tax Profit Margin | 0.0 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 0.0 |
| Effective Tax Rate | 0.0 |
| Effective Tax Rate - 5YEAR AVRG. | 0.0 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | -11 |
| Revenue per Employee | 26,023 |
| Net Income per Employee | -1,065,395 |
| Average Collection Period | 19 |
| Receivables Turnover | 16.0 |
| Day's Inventory Turnover Ratio | -30 |
| Inventory Turnover | -11.9 |
| Inventory/Sales | 113.6 |
| Accounts Payble/Sales | 668.99 |
| Assets/Revenue | 0.00 |
| Net Working Capital Turnover | 0.15 |
| Fixed Assets Turnover | 0.13 |
| Total Assets Turnover | 0.0 |
| Revenue per $ Cash | 0.08 |
| Revenue per $ Plant | 0.77 |
| Revenue per $ Common Equity | 0.08 |
| Revenue per $ Capital Invested | 0.07 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 1187.2 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 3382.1 |
| Research & Devlopment (R&D) as % of Revenue | 1212.0 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 1212.0 |
|
|  
| | |  |  | |
| |